In FY2025, sales amounted to 33,072 million yen, a 22.9% decrease YoY. For FY2026, sales are forecasted to reach 37,800 million yen, indicating growth. R&D expenses increased to 15.4 billion yen, and the next term forecasts an operating profit of 2.6 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4552-20260623-03.pdf","jir_short_summary":"In FY2025, sales amounted to 33,072 million yen, a 22.9% decrease YoY. For FY2026, sales are forecasted to reach 37,800 million yen, indicating growth. R&D expenses increased to 15.4 billion yen, and the next term forecasts an operating profit of 2.6 billion yen.","jir_summary":"### Performance Summary\nIn FY2025, sales were 33,072 million yen, a decrease of 22.9% from the previous year, but for FY2026, sales are projected to be 37,800 million yen, with an expected increase. R&D expenses increased to 15.4 billion yen, and an operating profit of 2.6 billion yen is planned for the next period. The main products, such as the mucopolysaccharidosis treatment drug \"Izargo\u00ae\" and growth hormone preparations, have continued steady sales, and proactive R&D is underway for future growth. Financially, total assets are 104.8 billion yen, net assets are 47.7 billion yen, and the equity ratio is 45.1%.\n\n### Outlook and Impact on Shareholders\nThe next period forecasts sales of 37,800 million yen, an operating profit of 2.6 billion yen, and net profit of 3 billion yen, with continued emphasis on R&D investments to strengthen the earnings base. Dividends are planned to remain at 20 yen per share. Through funding progress and new drug development, the company aims for long-term growth and shareholder returns. The company is also continuously considering share buybacks and capital policies to suppress share dilution and enhance corporate value.","jir_financial_highlights":"Sales: 33,072 million yen (Decrease of 22.9% YoY)\nNet loss attributable to owners of the parent: \u25b34,460 million yen (Compared to the same period last year -)\nNext period sales forecast: 37,800 million yen (Forecasted increase)","jir_category":"","jir_hashtags":"#JCRPharma, #FinancialResults, #JapanStocks","jir_key_figures":"Sales: 33,072 million yen (decrease of 22.9% YoY)\nNext period sales forecast: 37,800 million yen (expected increase)\nNet loss attributable to owners of the parent: \u25b34,460 million yen","jir_meta_title":"\u3010JCR Pharma\u30112026 Earnings Outlook and Financial Summary | June 2026","jir_meta_description":"Analysis of JCR Pharma's FY2025 financial results and FY2026 outlook. Planning sales of 37,800 million yen, R&D expenses of 15.4 billion yen, and a next period operating profit of 2.6 billion yen.","jir_og_title":"\u3010JCR Pharma\u30112026 Earnings Outlook and Financial Summary | June 2026","jir_og_description":"Detailed overview of JCR Pharma's FY2025 financial results and FY2026 outlook. Planning sales of 37,800 million yen, R&D expenses of 15.4 billion yen, and an operating profit of 2.6 billion yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Sales (million yen)\\\",\\\"data\\\": [33872, 33072, 37800],\\\"borderColor\\\": \\\"#36A2EB\\\",\\\"fill\\\": false}]}\"}, {\"jir_chart_id\": \"research_development_expenses\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"R&D Expenses Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"R&D Expenses (billion yen)\\\",\\\"data\\\": [110, 154, 150],\\\"backgroundColor\\\": \\\"#FF6384\\\"}]}\"}, {\"jir_chart_id\": \"net_income\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Net Income (million yen)\\\",\\\"data\\\": [5507, -4460, 3000],\\\"backgroundColor\\\": \\\"#4BC0C0\\\"}]}\"}, {\"jir_chart_id\": \"asset_total\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Asset Composition Ratio\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Current Assets\\\",\\\"Non-current Assets\\\"],\\\"datasets\\\": [{\\\"data\\\": [51487, 53361],\\\"backgroundColor\\\": [\\\"#FFCE56\\\",\\\"#4BC0C0\\\"]}]}\"}, {\"jir_chart_id\": \"equity_ratio\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Equity Ratio Trends\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"2024\\\",\\\"2025\\\"],\\\"datasets\\\": [{\\\"label\\\": \\\"Equity Ratio (%)\\\",\\\"data\\\": [54.2, 45.1],\\\"borderColor\\\": \\\"#9966FF\\\",\\\"fill\\\": false}]}\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-67741","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n